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Abstract The 4th edition of the World Health Organiza-
tion classification of tumors of hematopoietic and lym-
phoid tissues introduces many new items to the
classification scheme of the so-called indolent B cell
lymphomas. New proposed entities, such as splenic B cell
lymphoma/leukemia, unclassifiable, splenic diffuse red
pulp small B cell lymphoma, hairy cell leukemia variant,
pediatric follicular lymphoma, and pediatric marginal
zone lymphoma have been coined, and some definitions of
established diseases, such as chronic lymphocytic leuke-
mia or Waldenström’s macroglobulinemia have been
revised. One aspect of major importance is the recent
description of small clonal B cell populations, in part with
a CLL phenotype, and their relationship to B-CLL. Some
new subtypes or variants of follicular lymphoma with
distinct clinicopathologic and/or molecular genetic char-
acteristics have been described, including primary follic-
ular lymphomas of the duodenum and pediatric follicular
lymphomas. Furthermore, the impact of some probably
early, or precursor lesions, such as follicular lymphoma in
situ is discussed. Overall, we succinctly discuss the
essential elements of the revisions made in the updated
classification, and we identify potential opportunities for
refinement of new or provisional categories in subsequent
classifications.
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Introduction
In the 4th edition of the World Health Organization (WHO)
classification [1], many new items have been incorporated
in the classification scheme of the so-called indolent B cell
lymphomas. Thus, in the updated classification, splenic B
cell lymphoma/leukemia, unclassifiable, splenic diffuse red
pulp small B cell lymphoma, hairy cell leukemia variant,
pediatric follicular lymphoma, and pediatric marginal zone
lymphoma have been added as new proposed entities.
Based on the recommendations of international consensus
groups, some definitions, such as the definition of chronic
lymphocytic leukemia, Waldenström’s macroglobulinemia,
and plasma cell myeloma have been revised. The WHO
classification gives advice on how to deal with the recent
intriguing detection of small clonal B cell populations, in
part with a CLL phenotype, and the definition of
established CLL, and the recent descriptions of follicular
lymphoma in situ (Table 1).
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lymphomas
The classification of the indolent B cell lymphomas closely
follows the notion that B cell neoplasms tend to recapitulate
the stages of normal B cell maturation. They do frequently
lack further differentiation capacity, thus being similar to
“frozen” stages of lymphocyte development [1]. In normal
B lymphocyte development, naïve and often CD5+ B cells
circulate in the blood and also colonize the primary follicles
and follicular mantle zones of the B cell areas of the lymph
node. Mantle cell lymphoma (MCL) is the putative
neoplastic counterpart of these naïve CD5+ B cells. Upon
antigen contact, the naïve B cells migrate into the follicle,
proliferate, and form the germinal center (GC). In this
specialized lymphoid compartment, important modifica-
tions of the B cell receptor repertoire take place, such as
somatic hypermutation of the immunoglobulin-heavy
(IGH) and light-chain variable (IGV) gene regions, class
switching, and receptor editing. These modifications in the
Table 1 WHO histological classification of mature B cell neoplasms (Definitions that have changed or have been newly coined)
Indolent B cell neoplasms
2001 Classification 2008 Classification Notable aspects of 2008 classification
Chronic lymphocytic leukemia/small
lymphocytic leukemia
Chronic lymphocytic leukemia/small
lymphocytic leukemia
Explicit requirement for ≥5×10
9/L monoclonal B cells
with CLL phenotype, if extramedullary disease is
absent. Monoclonal lymphocytosis of undertermined
significance may be "precursor" lesion within the CLL/
SLL spectrum
Lymphoplasmacytic lymphoma/
Waldenstrom macroglobulinemia
Lymphoplasmacytic lymphoma As in 2008 definition
Waldenström’s macroglobulinemia Definition now incorporates the morphological diagnosis
of LPL with bone marrow involvement, and due
consideration given to the fact that IgM paraprotein
may be present in non-LPL lymphomas
Splenic marginal zone lymphomia Splenic B cell marginal zone lymphomia As in 2008 definition
Splenic B cell lymphoma/leukemia,
unclassifiable
Splenic diffuse red pulp small B cell
lymphoma
Diffuse proliferation of small-sized lymphocytes pre-
dominantly localized to the spleen and bone marrow
sinusoids but with villous projections. DBA44+, IgM+,
IgD-
Hairy cell leukemia-variant Variant cytological features intermediate between HCL
and B-PLL. Immunophenotype: DBA44+, CD11c+,
sIg++, CD103+, TRAP-/+, CD25-/+, CD103-, CD123-,
Annexin A1-.
Hairy cell leukemia Hairy cell leukemia As in 2008 definition
Extranodal marginal zone B cell
lymphoma of mucosa-associated lym-
phoid tissue (MALT-lymphoma)
Extranodal marginal zone B cell
lymphoma of mucosa-associated lym-
phoid tissue (MALT-lymphoma)
As in 2008 definition
Nodal marginal zone B cell lymphoma Nodal marginal zone lymphoma As in 2008 definition
Pediatric nodal marginal zone
lymphoma
Distinct predilection for males, and histologically
associated with proliferation around progressively
transformed germinal centers
Follicular lymphoma Follicular lymphoma As in 2008 definition. Recognition of in situ follicular
lymphoma
Pediatric follicular lymphoma (variant) Recognition of a distinct follicular lymphoma variant in
children distinct from adult disease and exhibiting a
favorable prognosis with durable remissions as
compared to adult disease
Extranodal follicular lymphoma
Primary intestinal follicular lymphoma Recognition of a distinct follicular lymphoma variant in
bowel (often in duodenum) with excellent prognosis.
Similar genetic features to nodal follicular lymphoma
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ity of the encoded antibody (affinity maturation) and are the
prerequisite for the high specificity of the B cells in the
secondary immune response. Ongoing IGV region gene
mutation is a hallmark of both reactive germinal centers as
well as the GC of follicular lymphoma (FL), thus making
FL the archetype of a germinal-center-derived lymphoma.
In the late GC reaction, centroblasts differentiate into
centrocytes, and those cells that have acquired high-
affinity IGV mutations will be rescued from apoptosis via
re-expression of BCL2 as well as IRF4/MUM1. Centro-
cytes then differentiate into either memory B cells or
plasma cells, with post-germinal center B cells being
characterized by highly mutated IGV genes, without
ongoing mutations. Post-germinal center memory B cells
circulate in the peripheral blood and colonize the follicular
marginal zones of lymph nodes, spleen, and mucosa-
associated lymphoid tissues (MALT). Marginal zone lym-
phomas of MALT, splenic, and nodal types correspond to
post germinal center memory B cells, with an inherent
propensity for homing and proliferation within their
respective tissue sub-compartments (e.g., the marginal
zone). Plasma cell myeloma is the neoplastic equivalent
of a bone-marrow-homing post-GC, terminally differentiat-
ed B cell. Apart from showing biological characteristics of
their corresponding normal cell type as delineated above,
mature indolent B cell lymphomas are also those lymphoid
neoplasias that are most intimately associated with distinct
chromosomal aberrations, such as the t(11;14) in mantle
cell lymphoma or the t(14;18) in FL. In most instances,
however, these primary aberrations do not suffice to fully
transform the cell, but are a prerequisite for further tumor
development, e.g., by prolonging the lifespan of a cell that
can then acquire secondary chromosomal alterations.
Disease variants/subtypes and new provisional entities
The basic defined categories and diagnostic principles in
the indolent B cell lymphomas, with some rare exceptions,
have been retained in the new WHO classification.
However, since the 2001 WHO Classification, several
subtypes and variants of diagnostic categories have
emerged, and some of those have been incorporated in the
updated version of the classification. One example for this
is the recognition of the existence of a Cyclin-D1-negative
variant of mantle cell lymphoma (MCL). These tumors do
show the identical gene expression profile and pattern of
secondary aberrations than their Cyclin-D1-positive coun-
terparts, but do not harbor the t(11;14) translocation.
Instead, they may show upregulation of Cyclins D2 and/
or 3 [2, 3]. The diagnosis of Cyclin-D1-negative MCL,
however, remains a challenge because, in the absence of the
t(11;14), no specific feature does characterize these tumors
apart from their cytology and growth pattern; therefore,
caution is advised.
Grading of follicular lymphoma
A great deal of discussion preceded—and accompanied—
the formulation of the new proposal for the grading of
follicular lymphoma. The authors initially discussed,
whether follicular lymphoma grade 3B should stay within
the category of FL at all, given its close cytomorphological,
immunophenotypic, and genetic resemblance to diffuse
large B cell lymphoma (“follicular variant of DLBCL”)
[4, 5]. It was also debated (at times fervently), whether,
instead of having three or four grades of FL, pathologists
should be encouraged to use a merely two-tiered grading
system: FL grade 3A biologically and clinically might be
very similar to FL grades 1 and 2, while only subtle
differences exist between FL grades 1 and 2.
However, while the consensus emerged that FL grade 3B
should remain within the category of follicular lymphoma,
many hematopathologists felt that FL grade 3Awas distinct
from FL grades 1 and 2. Therefore, it was decided that four
FL grades should be kept in principle, but—given their
common indolent nature—that it was not mandatory to
differentiate between FL grades 1 and 2. Other important
new amendments in the new WHO classification of follicular
lymphomas is that for grading purposes, the number of
transformed lymphocytes (centroblasts) may be estimated
(not necessarily counted) in ten consecutive hpf, and that any
area of diffuse large B cell lymphoma in a FL should be
reported as the primary diagnosis, with an estimate of the
proportion of DLBCL and FL present (e.g., DLBCL and
FL grade 2 instead of transformed follicular lymphoma).
Revised diagnostic criteria, monoclonal lymphocytosis
and in situ lymphomas
One important re-definition in the new WHO classification
deals with the relationship of lymphoplasmacytic lympho-
ma (LPL) and Waldenström’s macroglobulinemia (WM).
While the criteria for LP remain the same as in the WHO
2001, the definition of WM now incorporates the morpho-
logical diagnosis of LPL with bone marrow involvement,
taking into account that an IgM paraprotein may also occur
in other B cell lymphomas [6].
The definition of chronic lymphocytic leukemia in the
updated WHO classification has been revised to take into
account a recently recognized entity designated as mono-
clonal B cell lymphocytosis (MBL). Therefore, in the
absence of cytopenias and extramedullary tissue involve-
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9/L monoclonal B lymphocytes
(characteristically CD5+ and CD23+) in the peripheral
blood. In the absence of other defining features, the WHO
does not explicitly define a threshold of minimal BM
involvement to diagnose B-CLL, whereas the International
Workshop on chronic lymphocytic leukemia suggests 30%
of lymphoid cells. Similarly, the specific histologic features
that define “extramedullary involvement” (i.e., whether this
requires nodal enlargement or effacement) are not defined.
It is currently unclear, whether MBL may be a precursor
lesion of overt CLL [7, 8]; hence, the situation may be
similar to monoclonal gammopathy of undetermined
significance and its relation to overt plasma cell myeloma.
In situ follicular lymphoma
Intrafollicular or “in situ” follicular lymphoma refers to the
recent description of cases with a background of hyper-
plastic germinal centers harboring distinct areas with BCL2
overexpression in centroblasts and centrocytes. The signif-
icance of this finding is currently unclear, because
evolution to overt follicular lymphoma is not observed in
most individuals with this phenomenon [9]. The presence
of (isolated) reactive follicles in full-blown FL, on the other
hand, has recently been associated with low disease stage
[10]. It may be difficult, if not impossible, to distinguish
some cases of in situ follicular lymphoma (with follicular
colonization of few reactive follicles) from localized
follicular lymphoma with some spared reactive follicles.
According to the description given by Cong et al. [9], FL in
situ is a condition in which the overwhelming majority of
the follicles is reactive, while according to Adam et al. [10],
FL with preserved reactive germinal centers, represents
cases in which the follicles are almost exclusively neoplas-
tic. However, it is certainly difficult to draw a definite line
between the two conditions in all cases.
Disease variants/subtypes and new provisional entities
The 2008 WHO classification of hematopoietic and
lymphoid tissues has introduced a number of disease
variants that occur in particular age groups or that are
characterized by a distinct site of origin, or bear distinctive
clinical features. Among the first are the pediatric nodal
marginal zone lymphomas (MZL) and follicular lympho-
mas. Nodal MZL in the pediatric age group are usually
diagnosed in early disease stages, frequently in head and
neck lymph nodes. In contrast to their adult counterparts,
they often present in the outer borders of progressively
transformed germinal centers [11]. Pediatric FL occurs in
cervical lymph nodes and Waldeyer’s ring, but also in
extranodal sites with the testis being the best-described
localization [12]. As in pediatric MZL, the disease is often
localized. Most of the cases are BCL2 protein negative and
also lack the t(14;18) translocation. Most of them are grade
3 with large expansile follicles. A distinction from a
condition of florid follicular hyperplasia with clonal B cell
populations ascertained by either immunohistochemistry or
molecular biological techniques is not always clear-cut [13].
The provisional entity of splenic B cell lymphoma/
leukemia, unclassifiable has been coined to encompass B
cell lymphomas involving the spleen that are not readily
classifiable into one of the previously defined categories.
Hence, splenic diffuse red pulp small B cell lymphoma and
hairy cell leukemia variant are part of a spectrum of
lymphoid neoplasias not yet satisfactorily characterized. As
the name suggests, splenic diffuse red pulp small B cell
lymphoma involves the splenic tissue in a diffuse pattern
and is also seen in BM sinusoids. In peripheral blood, it
usually manifests with villous cytology. There is a certain
overlap with hairy cell leukemia variant (HCL-v) with both
lymphoid proliferations being positive for DBA44 and
negative for IgD. Lack of CD25, CD103, and Annexin A1
expression sets splenic diffuse red pulp small B cell
lymphoma apart from hairy cell leukemia, but borderline
phenotypes have been described. Hairy cell leukemia
variant (HCL-v) exhibits variant cytohematological features
and presents with cytologic features intermediate between
HCL and B-PLL. Unlike classical HCL, TRAP is negative
in HCL-v, and immunophenotyping usually reveals nega-
tivity for CD103 and Annexin A1.
Extranodal lymphomas
Following recent experience, the WHO classification of
2008 stresses—still more than that of 2001—the impor-
tance of anatomic site as a prognostic factor in extranodal
lymphomas. It has become clear that the same lymphomas
originating at different sites may show distinct differences
in biology and hence, clinical behavior. This is most
obvious in the diffuse large B cell lymphomas, but the
same also holds true for the indolent lymphomas. It is of
course an accepted paradigm in the low-grade extranodal
marginal B cell lymphomas of mucosa-associated lymphoid
tissue (MALT lymphoma), where there are subtle morpho-
logical differences in the cytomorphological presentation of
the disease. The most striking feature regarding site of
origin, however, is the fact that MALT-lymphoma-specific
translocations, such as the t(11;18), the t(14;18) IGH/
MALT1, or trisomies 3 and 18 are encountered at different
sites in a highly variable frequency [14]. This finding points
to an important impact of site, or of the site-specific
precursor lesion, to the oncogenetic pathways.
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Follicular lymphomas occurring at some extranodal sites
are regarded as variants in the new WHO classification
(2008) [1]. Localized disease and indolent clinical behavior
are typical features of primary cutaneous follicle center
lymphomas that predominantly arise in the head and neck
region. Primary testicular follicular lymphomas have
recently been described in children and young adults. They
are mostly grades 3A or 3B and, as a rule, are negative for
BCL-2 protein and do not carry the t(14;18), similar to
most pediatric FL (see above). Primary intestinal FL may
be regarded as an archetype of lymphoma that shows a
distinctly different biology and clinical course as compared
to its nodal counterpart: most patients, especially those with
primary duodenal FL, have localized disease, and their
prognosis is excellent. These features are somewhat
astonishing given the fact that, unlike cutaneous and
pediatric FL, primary duodenal FL do also harbor the t
(14;18) chromosome translocation. Therefore, the biologi-
cal relation between cutaneous, pediatric, and intestinal
variants with “garden variety” nodal FL is still unclear.
In conclusion, several amendments have been made
to the mature B cell lymphoma category in the WHO
classification of non-Hodgkin lymphomas. The future
definition of characteristic genetic aberrations and
opportunities for gene expression profiling of larger
cohorts of the rarer entities will lead to refinement of
the criteria for diagnoses of evolving categories, and
afford the discovery of novel clinicopathological entities
of malignant lymphomas.
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